or Try an Advanced Search...

    Treatment Of Chronic Lymphocytic Leukemia Stocks List

    Symbol Grade Name % Change
    TEVA B Teva Pharmaceutical Industries 0.04
    GMAB D Genmab A/S -3.51
    EGRX F Eagle Pharmaceuticals, Inc. 8.09
    View As Page of Charts
    Related Industries: Drug Manufacturers - Specialty & Generic Long-Term Care Facilities
    Related Stock Lists: Chronic Lymphocytic Leukemia Lymphocytic Leukemia Lymphoma Medicine Cancer Drugs Multiple Sclerosis Parkinson's Disease Pharmaceutical Active Pharmaceutical Ingredients Acute Myeloid Leukemia Advanced Cancer Advanced Cancers Allergy Amyloid Amyloidosis Angioplasty Antibodies Antibody Drug Conjugate Asthma

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Chronic Lymphocytic Leukemia stocks.

    Symbol Grade Name Weight
    ISRA C Market Vectors Israel ETF 8.54
    EIS C iShares MSCI Israel Capped Investable Market Index Fund 7.7
    FBT D First Trust Amex Biotech Index Fund 3.28
    PPH B Market Vectors Pharmaceutical ETF 2.68
    IZRL C ARK Israel Innovative Technology ETF 2.14
    View all Treatment Of Chronic Lymphocytic Leukemia ETFs...
    Compare ETFs
    Compare EIS to PPH Compare FBT to PPH Compare ISRA to PPH

        Treatment Of Chronic Lymphocytic Leukemia Stocks Recent News

        Date Stock Title
        May 2 TEVA Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
        May 2 TEVA Q1 2024 Corcept Therapeutics Inc Earnings Call
        May 2 TEVA Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
        May 1 GMAB Genmab Q1 2024 Earnings Preview
        May 1 GMAB Genmab: A Complicated Tale
        May 1 GMAB Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
        Apr 30 TEVA Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents
        Apr 30 GMAB Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
        Apr 30 GMAB Pfizer, Genmab cervical cancer therapy wins full FDA approval
        Apr 30 TEVA U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
        Apr 29 GMAB TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
        Apr 29 GMAB FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
        Related Industries: Drug Manufacturers - Specialty & Generic Long-Term Care Facilities
        Related Stock Lists: Chronic Lymphocytic Leukemia Lymphocytic Leukemia Lymphoma Medicine Cancer Drugs Multiple Sclerosis Parkinson's Disease Pharmaceutical Active Pharmaceutical Ingredients Acute Myeloid Leukemia Advanced Cancer Advanced Cancers Allergy Amyloid Amyloidosis Angioplasty Antibodies Antibody Drug Conjugate Asthma
        Treatment Of Chronic Lymphocytic Leukemia

        Treatment of chronic lymphocytic leukemia (CLL) depends on the stage of the disease and the patient's age and overall health. Treatment options may include watchful waiting, chemotherapy, targeted therapy, radiation therapy, and stem cell transplant.

        Browse All Tags